前往化源商城
入驻化源商城

品牌现货直购
供应商:我要出现这里







查看所有供应商和价格请点击:

56390-09-1生产厂家

56390-09-1价格

56390-09-1

56390-09-1结构式
56390-09-1结构式

化源商城直购

中文名 盐酸表柔比星
英文名 Epirubicin hydrochloride
中文别名 盐酸表阿霉素
英文别名 5,12-naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-, hydrochloride
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydro-1-tetracenyl 3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranoside hydrochloride (1:1)
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.α.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride
Pidorubicin hydrochloride
5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-, hydrochloride (1:1)
Ellence
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranoside hydrochloride
Epirubicin hydrochloride
(1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-arabino-hexopyranoside hydrochloride (1:1)
EINECS 260-145-2
(8S,10S)-10-{[(2R,4S,5R,6S)-4-Amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracen-5,12-dionhydrochlorid
EPIRUBICIN HCl
(8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
Epirubicin (hydrochloride)
描述 Epirubicin hydrochloride 是阿霉素的半合成的 L-阿拉伯糖衍生物,能够抑制 Topoisomerase,起到抗肿瘤的作用。
相关类别
靶点

Topoisomerase

体外研究 与阿霉素一样,表柔比星通过与DNA的复合物发挥其抗肿瘤作用,导致DNA损伤并干扰DNA,RNA和蛋白质的合成。表柔比星也可能影响细胞膜的完整性和活性。表柔比星引起的最大细胞杀伤发生在细胞周期的S期。随着浓度的增加,早期G2以及G1期和M期也会出现影响[1]。表柔比星显示出对抗大多数癌细胞的抗肿瘤活性。表柔比星对肝癌G2细胞具有细胞毒性,24小时IC50为1.6μg/ mL。 1.6μg/ mL表阿霉素诱导Hep G2细胞凋亡,过氧化氢酶活性增加50%,Se依赖型谷胱甘肽过氧化物酶活性增加110%,Cu,Zn超氧化物歧化酶增加172%,Mn-超氧化物歧化酶增加135%。 Epirbicin可增加NADPH-CYP 450还原酶的细胞表达,并降低GST-π的表达[2]。
体内研究 表柔比星对多种肿瘤类型具有临床活性,包括乳腺癌,恶性淋巴瘤,软组织肉瘤,肺癌,胸膜间皮瘤,胃肠癌,头颈癌,卵巢癌,前列腺癌,膀胱移行癌等[ 3]。剂量为3.5mg/kg的表柔比星抑制人乳腺肿瘤异种移植物R-27的肿瘤质量达74.4%[4]。
细胞实验 将Hep G2细胞(500个细胞/孔,单层)接种在96孔板中。第二天,在培养基中用表柔比星处理细胞。在孵育期结束时,加入15%体积的MTT染料溶液。在37℃温育1小时后,向每个孔中加入等体积的溶解/终止溶液(二甲基亚砜 - 氧化物),再孵育1小时。记录反应溶液在570nm处的吸光度。
参考文献

[1]. Cersosimo RJ, et al. Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue. J Clin Oncol. 1986 Mar;4(3):425-39.

[2]. Ozkan, A., et al. Epirubicin HCl toxicity in human-liver derived hepatoma G2 cells. Pol J Pharmacol, 2004. 56(4): p. 435-44.

[3]. Bonadonna, G., et al. Drugs ten years later: epirubicin. Ann Oncol, 1993. 4(5): p. 359-69.

[4]. Asanuma, F., et al. Antitumor activity of paclitaxel and epirubicin in human breast carcinoma, R-27. Folia Microbiol (Praha), 1998. 43(5): p. 473-4.

密度 1.61g/cm3
沸点 810.3ºC at 760 mmHg
熔点 185ºC dec
分子式 C27H30ClNO11
分子量 579.980
闪点 443.8ºC
精确质量 579.150757
PSA 206.07000
LogP 1.50360
外观性状 橙色-红色结晶固体
折射率 1.709
储存条件

保持贮藏器密封、储存在阴凉、干燥的地方,确保工作间有良好的通风或排气装置

稳定性

如果遵照规格使用和储存则不会分解,未有已知危险反应

计算化学

1、 疏水参数计算参考值(XlogP):

2、 氢键供体数量:7

3、 氢键受体数量:12

4、 可旋转化学键数量:5

5、 互变异构体数量:81

6、 拓扑分子极性表面积(TPSA):206

7、 重原子数量:40

8、 表面电荷:0

9、 复杂度:977

10、同位素原子数量:0

11、确定原子立构中心数量:6

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:0

14、不确定化学键立构中心数量:0

15、共价键单元数量:2

更多

1. 性状:未确定

2. 密度(g/mL,15ºC):未确定

3. 相对蒸汽密度(g/mL,空气=1):未确定

4. 熔点(ºC):185

5. 沸点(ºC):未确定

6. 沸点(ºC,14mmHg):未确定

7. 折射率:未确定

8. 闪点(°C):未确定

9. 比旋光度(ºC):未确定

10. 自燃点或引燃温度(ºC): 未确定

11. 蒸气压(kPa,25ºC):未确定

12. 饱和蒸气压(kPa,60ºC):未确定

13. 燃烧热(KJ/mol):未确定

14. 临界温度(ºC):未确定

15. 临界压力(KPa):未确定

16. 油水(辛醇/水)分配系数的对数值:未确定

17. 爆炸上限(%,V/V):未确定

18. 爆炸下限(%,V/V):未确定

19. 溶解性:未确定

毒理学数据:

急性毒性:女性静脉注射TDLo:1622mg/kg;大鼠经口LD50:1350mg/kg;大鼠腹膜腔LD50:10800μg/kg;大鼠皮下LD50:17600μg/kg;大鼠静脉注射LD50:17mg/kg;小鼠经口LD50:>2mg/kg;小鼠皮下LD50:37500μg/kg;小鼠静脉注射LD50:31500μg/kg;狗静脉注射LD50:2250μg/kg;

生态学数据:

对水是稍微有危害的不要让未稀释或大量的产品接触地下水、水道或者污水系统,若无政府许可,勿将材料排入周围环境。

CHEMICAL IDENTIFICATION

RTECS NUMBER :
QI9295750
CHEMICAL NAME :
5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyran osyl)oxy)- 7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacety l)-1-methoxy-, hydrochloride, (8S-cis)-
CAS REGISTRY NUMBER :
56390-09-1
LAST UPDATED :
199612
DATA ITEMS CITED :
9
MOLECULAR FORMULA :
C27-H29-N-O11.Cl-H
MOLECULAR WEIGHT :
580.03

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
1622 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Gastrointestinal - changes in structure or function of salivary glands Immunological Including Allergic - uncharacterized
REFERENCE :
LANCAO Lancet. (7 Adam St., London WC2N 6AD, UK) V.1- 1823- Volume(issue)/page/year: 2,629,1986
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1350 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
10800 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
17600 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
17 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
IYKEDH Iyakuhin Kenkyu. Study of Medical Supplies. (Nippon Koteisho Kyokai, 12-15, 2-chome, Shibuya, Shibuya-ku, Tokyo 150, Japan) V.1- 1970- Volume(issue)/page/year: 26,740,1995
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
37500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
31500 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
2250 ug/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
REFERENCE :
NIIRDN Drugs in Japan (Ethical Drugs). (Yakugyo Jiho Co., Ltd., Tokyo, Japan) Volume(issue)/page/year: -,200,1990

符号 GHS07 GHS08
GHS07, GHS08
信号词 Danger
危害声明 H302-H340-H350-H360
警示性声明 P201-P280-P301 + P312 + P330-P308 + P313
危害码 (欧洲) Xn
风险声明 (欧洲) 22-63-62-46-40
安全声明 (欧洲) 36/37/38-45-46
危险品运输编码 NONH for all modes of transport
RTECS号 QI9295750
海关编码 2932999099
海关编码 2932999099
中文概述 2932999099. 其他仅含氧杂原子的杂环化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0%
申报要素 品名, 成分含量, 用途
Summary 2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%